Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$1.63 USD
+0.04 (2.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.62 -0.01 (-0.61%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.63 USD
+0.04 (2.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.62 -0.01 (-0.61%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Zacks News
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
by Zacks Equity Research
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
by Zacks Equity Research
BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
by Zacks Equity Research
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Why Marijuana ETFs & Stocks Have More Room to Run
by Sanghamitra Saha
Marijuana stocks and ETFs are hot this year and can perform better in the coming days.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
Top Performing ETF Areas of February
by Sanghamitra Saha
Let's take look at the top ETF areas of February 2019.
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $79.07, marking a -0.16% move from the previous day.
Marijuana Stocks and ETFs: Risks and Rewards
by Neena Mishra
Pot stocks are soaring again. To learn more about risks and rewards of investing in marijuana stocks and ETFs, check out this Exploring ETFs video.
What Investors Need to Know About Investing in Marijuana Stocks
by Benjamin Rains
Let's look at what investors need to know about the marijuana industry and how to invest in the future of pot.
Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF
by Sweta Killa
Tilray's deal to acquire the hemp food maker Manitoba Harvest has bolstered the outlook of the already high-flying marijuana ETF.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $76.49 in the latest trading session, marking a -0.17% move from the prior day.
4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019
by Sanghamitra Saha
Marijuana stocks and related ETFs caught investors' attention last year, courtesy of its mysterious rally in mid-2018 on Canada's legalization of recreational marijuana in October. Let's take a look at whether the space will be able to maintain its rally in 2019.
Pot Stocks: Who Has the Best Earnings Chart?
by Tracey Ryniec
Pot stocks are entering the investing mainstream but do they have what it takes to compete against mature industries?
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $79.24 in the latest trading session, marking a -0.94% move from the prior day.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
Will Q4 Results Continue to Fuel Momentum in Marijuana ETF?
by Sweta Killa
Investors are keenly watching whether legalization is living up to the hype in the quarterly results of the cannabis stocks.
Buy the Dip in Marijuana Stocks & ETF?
by Sanghamitra Saha
Marijuana stocks and ETF slumped on Feb 6. Is this the time to buy?
Where to Find the Best Marijuana Stocks
by Tracey Ryniec
As the marijuana industry gets more complex, check out the Zacks Market Edge Podcast where host Tracey Ryniec
Pot Stocks are on a High: Play These Marijuana ETFs
by Sanghamitra Saha
As marijuana stocks soar into the new year, which ETFs should investors consider?
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
Here's Why Cannabis Stocks (ACB, CRON) Are Gaining Today
by Ryan McQueeney
Shares of several notable cannabis stocks, including Aurora Cannabis (ACB) and Cronos Group (CRON), were up more than 10% through early afternoon trading hours Monday.